Improving Drug Safety — A Joint Responsibility

Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo (Herausgeber)

Buch | Softcover

XXI, 338 Seiten

2011 | 1. Softcover reprint of the original 1st ed. 1991
Springer Berlin (Verlag)
978-3-642-64762-8 (ISBN)

Artikel merken

As the focus on pharmaceuticals has broadened from concern for their cost and effectiveness to their real and potential risks and benefits, a critical question has been raised: whose responsibility is it to improve drug safety? In April 1990, this question became the theme for a conference at Wolfsberg, Switzerland, near the shores of Lake Constance. Called an "international dialogue conference" by its organizers, the meeting brought together leaders from the pharmaceutical industry, regulatory authorities, academia, medicine, consumer organizations and the media. Opening addresses were given by representatives of the Council for International Organizations of Medical Sciences (CIOMS), the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the Swiss International Pharmaceutical Agency, and the RAD-AR Consortium. This book documents the papers presented and discussions held at this conference, which took the topic of risks and benefits of drug therapy one step further to responsibility. It includes a rich menu of issues for those who care about the evaluation of drug therapy, the ethics behind it, the expectations of the patient, and the role of traditional and nontraditional drug safety communica tions. The ideas expressed here come from different parts of the world but relate to common drug safety problems, observations, and scientific assessments; they provide insights into innovative approaches, cautious changes, and desired actions. The papers in this volume are broadly divided into conceptual perspectives (ethics, how the knowledge about drug risks and benefits is generated and appraised, the expectations in drug safety) and operational perspectives (communication, discussion, and action).

I: The Wolfsberg Dialogue.- 1. From Questions to Missions and Actions.- 2. The RAD-AR Agenda.- II: Welcoming Addresses.- 3. Council for International Organizations of Medical Sciences.- 4. International Federation of Pharmaceutical Manufacturers Associations.- 5. Intercantonal Office for the Control of Medicines.- 6. RAD-AR Consortium.- III: Ethical Perspectives.- 7. The Discipline of Ethics.- 8. Ethics and Health.- 9. A Biomedical Ethical Perspective.- 10. Corporate Ethics.- 11. Discussion.- IV: Generating Knowledge About Drug Risks.- 12. Categories of Risk and Worldwide Resources.- 13. International Risk Assessment.- 14. Resources Needed for Risk Assessment.- V: Generating Knowledge About Drug Benefits.- 15. Quality of Life and Health Status: Innovative Outcome Variables for Research in Population Health.- 16. The Socioeconomic Evaluation of Medicines: A New Dimension.- 17. Expanding Measures of Benefit in Socioeconomic Studies.- VI: Assessing the Risk/Benefit Relationship.- 18. Challenges in Benefit/Risk Appraisal.- 19. Analysis and Synthesis of Adverse Drug Reaction Evidence.- 20. The Complexities of Assessment.- 21. A Review of the Regulatory Process in Japan.- 22. Postmarketing Surveillance in Japan: An Industry View.- 23. Distortions in Risk Assessment.- 24. Weighing Risk/Benefit Assessment: Views of a Swedish "Regulator".- 25. Scientific Evaluations and Personal Judgments.- 26. Discussion.- VII: Expections in Drug Safety Communication.- 27. The Challenge of Communicating Drug Safety Information.- 28. The Media Perspective.- 29. The Culture of Weighing.- 30. Patient Package Inserts: Carriers of Consensus Information.- 31. The Patients' View.- 32. Patient Motivation.- 33. Japans's Other Drug Market: Exports via Tourists.- 34. Controlling Drug Safety:Making Cautious Changes.- 35. Discussion.- VIII: Experiences in Drug Safety Communication Through Traditional Channels.- 36. Principles, Experiences, and Desired Actions.- 37. Physician-Patient Communication and Decision Making.- 38. Problem-Oriented Drug Information Services.- IX: Responses Beyond Traditional Communication Channels.- 39. Manufacturer Standards for Communicating Risks and Benefits.- 40. Health Behavior Change via Community Education.- 41. Risk Perception: Analyzing Images and Fears.- 42. New Channels for the Patients.- 43. The Patients-in-the-Know Program.- 44. Information for the Public: A Swedish Example.- 45. Discussion.- X: RAD-AR Activities.- 46. International Overview.- 47. RAD-AR Council Japan.- XI: Reports and Recommendations from the Working Groups.- 48. Generating and Assessing Knowledge.- 49. Dialogue and Communication.- XII: Ethical Perspectives Revisited.- 50. Applying Ethics.- 51. Moral Common Sense.- 52. Guiding Principles.- XIII: An Agenda for Action.- 53. Future Directions.- 54. Wolfsberg Think Pieces.- 55. Bibliography.- 56. RAD-AR Bibliography.- 57. Curriculum Vitae of Authors and Editors.- 58. International Life Sciences Institute.- 59. International Medical Benefit/Risk Foundation - RAD-AR.- 60. Subject Index.

Erscheint lt. Verlag	26.9.2011
Reihe/Serie	Health Systems Research
Zusatzinfo	XXI, 338 p.
Verlagsort	Berlin
Sprache	englisch
Maße	170 x 242 mm
Gewicht	622 g
Themenwelt	Medizin / Pharmazie ► Allgemeines / Lexika
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Pharmazie
Schlagworte	addiction therapy • Arzneimittel • Arzneimittelsicherheit • Arzneitherapie • Arzneitherapie / Arzneibehandlung • Assessment • Bewertung der Therapie mit Arzneimitteln • Drogenrisiko/Nutzen-Bewertung • Drogensucht • Drug • Drug risk/benefit appraisal • drug safety communications • ethics • regulatiory fo evaluation of drug therapy • regulatorische Trends • Research • scientific assessments • Suchttherapie • therapy • wissenschaftliche Bewertung
ISBN-10	3-642-64762-6 / 3642647626
ISBN-13	978-3-642-64762-8 / 9783642647628
Zustand	Neuware